Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.51 |
| ▸ | NOS1 | P29475 | 7/20 | 0.51 |
| ▸ | NOS3 | P29474 | 5/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826661 | 0.95 | NOS2 (0.53) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL21250709 | 0.91 | NOS2 (0.47) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL10279977 | 0.89 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL21590075 | 0.89 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL13536316 | 0.86 | NOS2 (0.49) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL10187362 | 0.86 | NOS2 (0.49) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL10279986 | 0.84 | NOS2 (0.49) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL25661126 | 0.81 | GSR (0.50) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL25660443 | 0.81 | GSR (0.50) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL23809592 | 0.81 | NOS2 (0.47) | NOS2NOS1NOS3CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| EP-4389145-A2 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES | Ambrx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | AMBRX, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220411469-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-20130237481-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. | 2013-09-12 | — | — | US | disclosed |
| US-8476411-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130150564-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166559-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012024452-A2 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-2399893-A2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | Ambrx, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011087810-A1 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011087808-A1 | MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | NOS2 1049/4885NOS1 4161/4885NOS3 3388/4885 |
| US-20220411469-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | DDOST, DAD1, PTMS | NOS2 209/4885NOS1 206/4885NOS3 97/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | NOS2 1667/4885NOS1 2210/4885NOS3 2480/4885 |
| US-20130237481-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | RXFP1, RXFP2, RXFP3 | NOS2 396/4885NOS1 624/4885NOS3 505/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | NOS2 4241/4885NOS1 4297/4885NOS3 3906/4885 |
| US-20230348547-A1 | MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES | CSF3R, GMFG, HDGF | NOS2 2298/4885NOS1 3226/4885NOS3 2522/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | NOS2 2216/4885NOS1 2705/4885NOS3 2785/4885 |
| US-20230028168-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | NOS2 1488/4885NOS1 2469/4885NOS3 1453/4885 |
| US-11542310-B2 | Modified bovine G-CSF polypeptides and their uses | CSF3R, GMFG, HDGF | NOS2 2298/4885NOS1 3226/4885NOS3 2522/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | NOS2 396/4885NOS1 624/4885NOS3 505/4885 |
| US-20130150564-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | NOS2 2852/4885NOS1 3622/4885NOS3 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.